Werewolf Therapeutics, Inc. (HOWL) - What Are Brokerages Thinking About This Stock?

Werewolf Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst consensus is “Hold”: Of six firms covering Werewolf Therapeutics, four rate it Hold, one Sell and one Buy; the average 12-month price target is $2.50.
  • Shares opened at $1.03, below the average analyst target, and have traded between $0.27 and $1.20 over the past 52 weeks.
  • Werewolf reported a quarterly loss of $0.20 per share, beating analysts’ expected loss of $0.22; analysts forecast a full-year loss of $0.89 per share.
  • MarketBeat previews top five stocks to own in December.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $2.50.

HOWL has been the topic of several recent analyst reports. Wall Street Zen raised shares of Werewolf Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. Zacks Research cut shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings upgraded shares of Werewolf Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 10th.

View Our Latest Stock Analysis on Werewolf Therapeutics

Werewolf Therapeutics Stock Down 1.9%

Shares of NASDAQ HOWL opened at $1.03 on Thursday. The business has a 50-day moving average price of $0.99 and a 200 day moving average price of $0.71. The stock has a market cap of $50.06 million, a PE ratio of -1.72 and a beta of 0.55. Werewolf Therapeutics has a 52-week low of $0.27 and a 52-week high of $1.20.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Friday, November 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. Sell-side analysts anticipate that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in HOWL. Bank of America Corp DE bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at approximately $112,000. Covestor Ltd purchased a new stake in shares of Werewolf Therapeutics in the third quarter worth $124,000. Squarepoint Ops LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth $37,000. BlackRock Inc. bought a new position in shares of Werewolf Therapeutics during the second quarter valued at $37,000. Finally, Virtu Financial LLC increased its holdings in shares of Werewolf Therapeutics by 99.6% during the third quarter. Virtu Financial LLC now owns 90,749 shares of the company's stock valued at $84,000 after acquiring an additional 45,282 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company's stock.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body's immune response against tumors. The company's INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.

See Also

Analyst Recommendations for Werewolf Therapeutics (NASDAQ:HOWL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Werewolf Therapeutics Right Now?

Before you consider Werewolf Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.

While Werewolf Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines